Cancel

Current Challenges and New Opportunities in Hematopoietic Stem Cell Transplant

STATEMENT OF NEED Hematopoietic stem cell transplant is a potentially curative therapy for patients with hematologic malignancies. There are 2 primary types of HSCT: autologous, where the cells are taken from the patient, and allogeneic, where the cells come from a matched sibling donor or an unrelated donor. Advances in HSCT include the introduction of reduced-intensity conditioning regimens that allow transplant in older patients and alternative graft sources that afford a donor for nearl...
i3 Health

Current Standards and Best Practices in the Management of Tumor Lysis Syndrome

STATEMENT OF NEED Tumor lysis syndrome (TLS) is a rare, potentially life-threatening oncologic emergency typically associated with chemotherapy-induced tumor cell death in which potassium, phosphate, and nucleic acids are released into the bloodstream. This release of intracellular materials results in severe metabolic abnormalities such as hyperuricemia and hyperphosphatemia, which may cause acute renal injury, and hypokalemia and hypocalcemia, which may cause seizures, neuromuscular sympt...
i3 Health

New Thinking, New Strategies in the Treatment of Advanced NSCLC Without Driver Mutations

STATEMENT OF NEED Of the estimated 228,150 patients diagnosed with lung cancer in the United States each year, 84% have non-small cell lung cancer (NSCLC). Most patients with NSCLC present with advanced disease, which is highly resistant to chemotherapy. The 5-year survival rates remain dismal (18%). Recently, the use of tumor histology in determining optimal treatment strategies and relevant molecular biomarkers to further refine selection of novel therapies has improved outcomes for some ...
i3 Health

New Clinical Perspectives in the Management of Myelofibrosis

STATEMENT OF NEED Myelofibrosis is a rare type of myeloproliferative neoplasm—a heterogenous group of hematopoietic disorders—that affects approximately 13,000 individuals in the United States. As symptoms do not typically manifest in early stages, patients with myelofibrosis often present with advanced disease. The presence of comorbidities precludes most from allogeneic stem cell transplant, the only potentially curative treatment option available. Due to the dearth of effective treat...
i3 Health

Optimizing the Clinical Outcomes of Patients With Immune Thrombocytopenia

STATEMENT OF NEED Immune thrombocytopenia (ITP) is a heterogeneous disorder with variable clinical features that range from asymptomatic thrombocytopenia to bothersome bruising to life-threatening intracranial hemorrhage. The lack of specific diagnostic criteria remains an important unmet need. Bleeding events are the most common clinical manifestation of ITP but are unpredictable with current laboratory testing. Many patients do not exhibit significant bleeding even in the setting of sever...
i3 Health

Enhancing Treatment Experiences in Castration-Resistant Prostate Cancer: The Nurse's View

STATEMENT OF NEED Prostate cancer is the most common tumor type affecting men in the United States, with an estimated 174,650 new cases reported each year. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significa...
i3 Health

New Thinking, New Strategies in Advanced Urothelial Carcinoma

STATEMENT OF NEED Bladder cancer is the sixth most common malignancy among adults in the United States. Approximately 80,470 new cases are diagnosed annually and 17,670 people die of the disease. More than 90% of patients with bladder cancer have the urothelial carcinoma subtype, which has a high rate of recurrence whether it is low or high grade. Approximately half of all bladder cancers are diagnosed in situ, for which the 5-year relative survival rate is 95%. For tumors diagnosed as a lo...
i3 Health

Optimizing Personalized Care Plans for Patients With Advanced Non-Small Cell Lung Cancer

STATEMENT OF NEED An estimated 228,150 new cases of lung cancer are reported in the United States annually, and 142,670 people die of the disease. The major subtypes are non-­small cell (84%) and small cell (13%). Most patients with lung cancer are diagnosed at a locally advanced or metastatic stage, making systemic therapy the cornerstone of management. Although 70% of patients receiving first-line classical doublet chemotherapy demonstrate clinical benefit, most develop progressive disea...
i3 Health

Nursing Management of Myelofibrosis: Controlling Symptoms and Optimizing Patient Quality of Life

STATEMENT OF NEED Myeloproliferative neoplasms are a heterogeneous group of hematopoietic disorders that includes myelofibrosis, polycythemia vera (PV), and essential thrombocythemia (ET). These malignancies affect approximately 13,000, 134,000, and 148,000 individuals in the United States, respectively. As symptoms do not typically manifest in early stages, patients with MPNs often present with advanced disease. The presence of comorbidities precludes most from potentially curative allogen...
i3 Health

Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care

STATEMENT OF NEED Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites (eg, cortical bone). Approximately 32,270 new cases of MM are diagnosed in the United States annually and 12,830 people die of the disease. Although the tumor cells remain primarily within the bone marrow, they can cause a number of complications, including localized bone destruction, anemia, decreased immunity to infection, and kid...
i3 Health

Virtual Tumor Board: Diagnosis and Management of Myelodysplastic Syndromes

STATEMENT OF NEED Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic disorders derived from an abnormal multipotent progenitor cell, characterized by ineffective hematopoiesis, bone marrow failure, and peripheral blood cytopenias. Survival in MDS ranges from a median of 5.3 years in lower-risk patients to as little as 0.8 years in higher-risk patients. Mortality is usually a result of infection, hemorrhage, and/or iron overload secondary to red blood cell transfusion...
i3 Health

Exploring Novel Treatment Strategies for Metastatic Colorectal Cancer

STATEMENT OF NEED Colorectal cancer (CRC) is the third leading cause of cancer death among men and women in the United States. An estimated 145,600 new cases are diagnosed annually and 51,020 people die of the disease. When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because CRC initially exhibits no symptoms and the use of routine screening is suboptimal, most patients are diagnosed at later stages. Approximately 21% of patients present with m...
i3 Health

Innovations and New Practices in Internal Medicine 2020

The State of the Art in Internal Medicine This Harvard Medical School CME program—among the highest-rated HMS CME courses--provides a comprehensive update of the most important changes impacting Internal Medicine and guidance to incorporate these advances into everyday clinical practice to improve patient outcomes. Practical, Fast-Paced, Case-Based Education The educational experience is highly interactive and fast paced, and draws upon real-life cases. The course is designed and led by H...
Harvard Medical School

BMTCN® Exam Review - Miami

This program is designed for BMT oncology nurses seeking a review in preparation for the ONCC® Blood & Marrow Transplant Certified Nurse (BMTCN®) Exam. The review will focus on the following categories from the 2016 test content outline: indications for transplantation, types of transplants and stem-cell sources, pretransplant care, preparative regimens, stem-cell infusion, graft-versus host disease, post-transplant care, survivorship and professional practice. This is not an introductory co...
MED-ED

Multi-Modality Management of Stage IV Melanoma in the Era of Immunotherapy

Target Audience This activity is intended for all surgeons and other health care professionals who are involved in the treatment of patients with melanoma. Program Overview Recent clinical trials suggest new options for neoadjuvant and adjuvant treatments for advanced melanoma. Surgical oncologists need to become familiar with these data to provide optimal treatment to their patients. This webinar is based on the SSO 2019 session. Learning Objectives Upon completion of this activity...
Society of Surgical Oncology

Novel Treatment Advances for Upper Tract Urothelial Carcinoma (UTUC)

Target Audience This activity is intended for urologists, medical/genitourinary oncologists, surgeons, and other health care professionals (primary care physicians, physicians-in-training, urology nurses, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with UTUC. Learning Objectives At the conclusion of this activity, participants will be able to: Adopt diagnostic and prognostic me...
Postgraduate Institute for Medicine and PlatformQ Health Education, LLC

Internal Medicine Comprehensive Review and Update 2020

This CME program from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital provides comprehensive instruction to ensure clinicians are current with the latest evidence and best practices for: • Cardiovascular Medicine • Pulmonary Medicine • Critical Care • Hematology and Oncology • Mind-Body Medicine • Infectious Diseases • Gastroenterology • Endocrinology • Rheumatology • Nephrology • Travel Medicine • Allergy and Immuno...
Harvard Medical School

Cutaneous Squamous Cell Carcinoma: Managing Advanced Disease in the Era of Immunotherapy

Most cases of cutaneous squamous cell carcinoma (cSCC), a common cancer, are recognized early and treated successfully with surgery. A small percentage of patients develop advanced or metastatic disease, in which case data to guide treatments are sparse and management depends on a patient’s level of disability and comorbidities. Because patients with de novo or post-surgical advanced or metastatic cSCC are rare, oncologists aren’t always acquainted with pathophysiology, recommendations for...
University of South Florida and Rockpointe

Shaping the Future of Myeloma Treatment

To help hematologist-oncologists keep pace with new advancements in multiple myeloma therapeutic regimens and management strategies, Shaping the Future of Myeloma Treatment features a roundtable discussion in which a panel of myeloma experts addresses a number of key clinical topics. Learners who participate in these activities will be expected to improve their ability to individualize treatment plans, based on genomics and risk stratification, to achieve durable remission while minimizing tox...
This CME-certified enduring activity is jointly provided by Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation.

Intensive Review of Internal Medicine

The Acclaimed Clinical Update and Board Review With more than 120 interactive lectures, case discussions, and board preparation sessions, this CME program is the most comprehensive review of internal medicine offered by the clinical faculty of Harvard Medical School. One of the highest-rated Harvard Medical School CME courses, it sold out the last two years, so early registration is advised. It offers accelerated learning: ► For clinicians seeking a practical and comprehensive review ...
Harvard Medical School

Update in Clinical Cardiology

The Comprehensive 2020 Update for Clinical Cardiology Evaluation • Treatment • Patient Care • Procedures • Challenging Cases This Harvard medical School CME program provides a comprehensive review of state-of-the-art practices to diagnose and treat patients with cardiovascular conditions. Led by the leading clinical faculty of Harvard Medical School and the Massachusetts General Hospital (MGH) Corrigan Minehan Heart Center, Update in Clinical Cardiology ensures attendees are current ...
Harvard Medical School

Thrombosis and Thromboembolism 2020

Offered only once every 2 years, this special Harvard Medical School CME course provides a comprehensive review of the most important changes and advances impacting the care of patients who have—or are at risk for—thrombosis and thromboembolism. Updates in diagnosis, treatment and prevention are provided by world-renowned experts and Harvard Medical School’s leading clinical faculty. The curriculum includes: • New options for testing and diagnosis of thrombotic disorders • Importan...
Harvard Medical School

Eradication of Minimal Residual Disease in Multiple Myeloma: The Role and Timing of ASCT

Advances in multiple myeloma (MM) management have equipped oncology health care providers with the tools and strategies for achieving treatment responses in up to 100% of patients, with as many as 80% reaching a complete response (CR). However, achieving a CR does not always predict long-term survival, and most patients ultimately relapse as a result of the persistence of minimal residual disease (MRD) after treatment. MRD cannot be detected with conventional, low-sensitivity evaluation method...
Albert Einstein College of Medicine

New Paradigms in the Management of Locally Advanced or Metastatic CSCC

In this activity, Dr. Michael Wong explains how to apply evidence and evidence-based recommendations to the selection of radiation, surgery, and/or systemic pharmacologic therapy. Later, he is joined by Dr. Chrysalyne Schmults to discuss a unique patient case.
The France Foundation

Obesity and Cancer

Intended Audience Physicians, Nurse Practitioners, Registered Dietitians, Registered Nurses. Learning Objectives Upon completion of this activity, the participant should be able to: To review the evidence linking lifestyle factors to cancer outcomes To review the randomized trials of lifestyle change in cancer survivors and discuss on-going work in this area To discuss the American Society of Clinical Oncology Obesity Initiative and other efforts to help cancer survivors adopt health...
Dannemiller

Managing Opioid-Induced Constipation: Translating Guidelines Into Patient Care

Constipation, the most common side effect of chronic opioid therapy, is a constellation of symptoms that includes infrequent or incomplete bowel movements, abdominal pain or bloating, and the need to strain when having a bowel movement.1,2 In addition to constipation-related discomfort, opioid-induced constipation (OIC) produces significant health and quality-of-life burdens.3,4 Poorly managed OIC can lead patients to reduce or skip opioid doses, thereby decreasing adherence, increasing pain-r...
Integritas Communications

Current Obstacles in Myeloma Management: Debating the Evidence

ACTIVITY DESCRIPTION The clinical multiple myeloma arena has seen significant advances in treatment, diagnosis, imaging, disease monitoring, and supportive care. The approval of several new agents has led to expanded criteria for earlier-stage diagnosis in some higher-risk patients with smoldering multiple myeloma (SMM), though questions remain regarding optimal treatment of other SMM patients. Treatment advances have improved median survival; nevertheless, prognosis remains poor for some pat...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Exploring Nuances Among Targeted and Immune Checkpoint Therapies in Melanoma: Focus on Mechanisms, BRAF Mutation, and Achieving a Durable Response

The treatment of advanced melanoma has shifted dramatically since the introduction of immune checkpoint inhibitors and BRAF/MEK inhibitors. Now, community oncology clinicians have multiple treatment options for their patients with stage III and IV disease that include both targeted and immunotherapies. However, treatment selection is highly complex, requiring consideration of multiple patient-, disease-, and treatment-related variables. It is therefore critical to provide community oncology cl...
Paradigm Medical Communications, LLC.

Decades in Waiting: Practice Changes in the Treatment of AML - Spotlight on Enasidenib

Since the treatment modalities for AML have remained relatively stagnant for decades, the approval of enasidenib is much needed as it affords patients a first-in-class, oral, single-agent targeted therapy for a difficult to treat diagnosis. This application-based continuing pharmacy education course provides a 'journal club format' discussion for pharmacists and student pharmacists to evaluate the phase 1/2 trial of enasidenib. Participate to review the safety and efficacy of enasidenib and di...
CEI

Quelling an Internal Civil War: New and Emerging Treatments for Graft-vs-Host Disease

Target Audience This educational activity has been designed for hematologists/oncologists, oncology and hematology fellows, and other members of the oncology care team who need to be aware of recent and emerging advances the prevention and treatment of GvHD. Statement of Need/Program Overview The leading cause of non-relapse post- allogeneic hematopoietic stem cell transplant mortality is GvHD manifesting as immunobiological warfare waged by the donor cells against multiple organ systems ...
The University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education, Inc

Immunotherapy Collaborative of Oncology Networked Communities

Target Audience This initiative is designed to meet the educational needs of oncologists, emergency care physicians, oncology pharmacists, oncology nurses and other healthcare professional involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy. Program Overview This case-based enduring activity will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy. ...
Med Learning

MCL Patient Exam in the Era of Targeted Therapies: Workup, Prognosis, Treatment, and Monitoring

The rapid evolution of treatment advances in mantle cell lymphoma (MCL) make treatment a complex and challenging proposition. Though several randomized, controlled trials on the use of targeted agents in MCL have been conducted, there are limited published, randomized data providing definitive guidance on treatment selection, duration of treatment, management of treatment-related toxicities, and disease outcomes across different lines of therapy. This activity has been developed to help cl...
Jointly provide by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd

CLL Patient Exam in the Era of Targeted Therapies: Workup, Prognosis, Treatment, and Monitoring

The rapid evolution of treatment advances in chronic lymphocytic leukemia (CLL) make treatment a complex and challenging proposition. Though several randomized, controlled trials on the use of novel targeted biologic agents in CLL have been conducted, there are limited published, randomized data providing definitive guidance on treatment selection (including drug combinations and sequencing therapy), duration of treatment, management of treatment-related toxicities, and disease outcomes across...
Jointly provide by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd

Precision Medicine in Immuno-Oncology: The Evolving Role of Current and Emerging Biomarkers

Patient selection remains a major challenge for the field of immuno-oncology, and the role of biomarkers continues to evolve as new data are released and novel targets are identified. In addition, as the therapeutic landscape continues to change with new indications, combination regimens, and novel immuno-oncology agents, the role of biomarkers will continue to evolve. As a result, many oncology clinicians and pathologists have difficulty remaining up to date with the latest data and best prac...
Educational Review Systems, Inc. and Paradigm Medical Communications, LLC

Recent Developments in Immuno-oncology: Biomarkers, Pan-tumor Studies, Novel Treatment Combinations, and the Management of Adverse Events

Target Audience This initiative is designed to meet the educational needs of oncologists, oncology pharmacists, oncology nurses, and other healthcare professionals and teams involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy. Program Overview This whiteboard preceptorship will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy. Learning Objec...
Med Learning Group

RME Hot Seat: Prognosis, Treatment Choice, and Risk Management for CLL and MCL

With the emergence of new targeted therapies and new prognostic indicators and goals of treatment, the clinical management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)—for patients in the frontline and relapsed/refractory settings—has evolved significantly. In this Q&A-based activity, our experts provide practical, evidence-based answers to questions relating to several of the most consequential changes in CLL/MCL patient care, including diagnostic and prognostic...
Jointly provide by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd

Optimizing Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

The rapid evolution of treatment advances in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) make treatment a complex and challenging proposition. Though several randomized, controlled trials on the use of targeted agents in MCL and CLL have been conducted, there are limited published, randomized data providing definitive guidance on treatment selection, duration of treatment, management of treatment-related toxicities, and disease outcomes across different lines of therapy. ...
Jointly provide by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd

Strategies for Neuroprotection, Relapse Prevention, and Mortality Reduction in Patients with Schizophrenia

Target Audience This education activity is directed towards OB-GYNs, medical oncologists, surgical oncologists, radiation oncologists, primary care physicians, such as family practitioners and internists, and radiologists. Program Overview Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T-cell lymphoma and is a distinct entity from systemic ALCL. In the United States, the FDA began to recognize reports of ALCL and a potential association with breast impla...
Physicians’ Education Resource®, LLC.

Board Vitals Family Medicine MOC Re-Certification Question Bank and Review

Board Vitals Family Medicine MOC Re-Certification Question Bank and Review contains over 1500 ABFM and AOBFP Family Medicine MOC targeted review questions. The Board Vitals FM qbank offers questions that are directly relevant to the exam: multiple choice questions (mostly focused around patient scenarios) with a single best answer. Board Vitals Family Medicine MOC Re-Certification Question Bank Features: • Take the exam in review mode or timed mode to simulate real FM exam conditions • ...
Board Vitals

Management of Cancer Pain: Current Guidelines

STATEMENT OF NEED Cancer patients often experience a range of symptoms that negatively impact their quality of life. Among the most debilitating is pain. Despite efforts to increase awareness, cancer pain is still underdiagnosed and undertreated and patients do not obtain complete relief. Although numerous management guidelines for cancer pain have been developed, most health care practitioners do not universally apply them. As such, there remains a considerable gap in the management of pai...
i3 Health

Board Vitals Neurology Board Review Question Bank and Study Program

The Board Vitals Neurology Board Review Question Bank and Study Program is targeted to the ABPN Neurology Board Exam and the RITE (In-Service Exam).  The question bank is offered on computers, laptops, tablets and mobile devices. The course is one of the most comprehensive Neurology study resources - with over 1500 Questions targeted to Board Level difficulty. The BoardVitals Neurology Board Review Question Bank and Study Program covers course materials from Basic Neuroscience to Congenital...
Board Vitals

Board Vitals ENT Board Review, Otolaryngology Board Review and Question Banks

Board Vitals ENT Board Review, Otolaryngology Board Review and Question Banks is targeted to the ABO Otolaryngology Board exam, the OTE (in-training exam), and AOBOO exam. BoardVitals ENT Board Review, Otolaryngology Board Review and Question Banks features Over 850 Board Exam type questions ranging from otology and facial plastic and reconstructive surgery to pediatric otolaryngology and head & neck oncology.
Board Vitals

Board Vitals USMLE Step 3 Board Review Questions

Board Vitals USMLE Step 3 Board Review Questions: • 1200 USMLE Step 3 board review questions • Individualized learning • Ability to flag questions for further review • Question are structured by category • Timed and review modes available • Detailed explanations associated with each question
Board Vitals

Board Vitals Internal Medicine Board Review Question Bank and Study Program

The Board Vitals Internal Medicine Board Review Question Bank and Study Program covers topics from Allergy and Immunology to Pulmonary topics - all of the subjects covered on the Internal Medicine Board Exam.  The bank offers over 1200 questions targeted to the ABIM and ABOIM exams.  The Internal Medicine review is highly interactive, offers high yield questions, and offers related images in a manner similar to the board exams.
Board Vitals

Osler Radiation Oncology Online Review

The Osler Institute utilized state of the art equipment to record the comprehensive Radiation Oncology Review Course and bring it to you! These audio files are stored “in the cloud” so you can stream them anywhere, anytime, as long as you have an internet connection – your learning experience is almost like being at the live activity, but without travel costs and time away from your practice. The Osler Radiation Oncology Review also offers a variety of live Radiation Oncology board revie...
Osler Institute

Osler Pediatrics Online Review

After completing the Osler Pediatrics Online Review, you will be able to: • Discuss updated patient management strategies for the following areas: internal medicine, nephrology, immunology, endocrinology, adolescent medicine, neonatology, otolaryngology, radiology, genetics and behavioral pediatrics • Confidently interpret laboratory finding, EKG's and other graphic representations of body function for specific patient presentations • Develop appropriate diagnosis and treatment plans ...
Osler Institute

Osler Obstetrics And Gynecology Online Video Review

Topics covered by the Osler Obstetrics And Gynecology Online Video Review include: Basic OB, Maternal and Fetal Physiology, Clinical Genetics and Teratology, Prenatal Diagnosis, OB Ultrasound, Antenatal Care and Monitoring, Abnormal Pregnancy Management, OB Emergencies, Neuro, Psych and GI disorders in Pregnancy, Trauma In Pregnancy, Pregnancy Loss: SAB, IUFD, Isoimmunization, Ambulatory Care, Genital Tract Infections, Systemic STD's, Vulvar Skin Conditions, Pediatric Gynecology, Breast Condi...
Osler Institute

Osler Surgery MOC Online Review

The Osler Institute utilized state of the art equipment to record the comprehensive Radiation Oncology Review Course and bring it to you! These audio files are stored “in the cloud” so you can stream them anywhere, anytime, as long as you have an internet connection – your learning experience is almost like being at the live activity, but without travel costs and time away from your practice. The Osler Radiation Oncology Review also offers a variety of live Radiation Oncology board revie...
Osler Institute

Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy

STATEMENT OF NEED Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to treatment dose reductions or discontinuation in severe cases. In one study of 123 patients receiving taxane therapy for breast cancer, 17% required dose reductions because of CIPN (Bhatnagar et al, 2014). Whereas in some patients the symptoms of pain, numbness, and tingling improve with time, in others, there is progression with permanent nerv...
i3 Health

Management of Venous Thromboembolism in Ambulatory Patients With Cancer

STATEMENT OF NEED Venous thromboembolism (VTE) is a common and potentially life-threatening complication in patients with cancer. There are two main types of VTE: deep vein thrombosis (DVT) and pulmonary embolus (PE), which can cause right heart failure, cardiopulmonary collapse, and death (Ozaki & Bartholomew, 2012). Patients who develop PE require hospitalization, increased oxygen requirements, and the need for temporary and/or long-term anticoagulation. These complications, in turn, lead...
i3 Health

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.